Wayback Machine
Nov DEC Jan
Previous capture 19 Next capture
2014 2015 2016
1 captures
19 Dec 15 - 19 Dec 15
sparklines
Close Help
Skip to main content

Access brought to you by: LOCKSS

Login

MD Conference Express
Advanced Search

Main menu

  • HOME
  • BROWSE BY CONFERENCE
  • BROWSE BY DISCIPLINE
    • -- All Disciplines --
    • Anesthesiology
    • Cardiology & Cardiovascular Medicine
    • Dentistry
    • Dermatology
    • Endocrinology, Diabetes & Metabolism
    • Emergency Medicine & Critical Care
    • Hematology
    • Hepatology
    • Infectious Diseases
    • Nephrology
    • Neurology
    • Nutrition
    • Obstetrics & Gynecology
    • Oncology
    • Ophthalmology
    • Orthopaedics & Sports Medicine
    • Psychiatry & Psychology
    • Pulmonary & Respiratory Medicine
    • Radiology
    • Rheumatology
    • Veterinary Medicine
  • ABOUT
    • About Us
    • International Medical Advisory Board
    • Reprints
    • Librarian resources
    • Contact us
    • Help

Gastrointestinal Cancers

  • Imatinib Dose Interruption in GIST: High Progression Risk for 3-Year Responders
  • Primary Prevention in Global Oncology: What Can We Gain?
  • A Randomized, Controlled, Double-Blind Phase 3 Study of Bevacizumab/Interferon-α2a vs Placebo/Interferon- α2a as First-line Therapy in Metastatic Renal Cell Carcinoma
  • Updated Efficacy Results from XELOX1/NO16966, a Randomized Phase 3 Trial in First-Line Metastatic Colorectal Cancer

Pages

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Other Products from SAGE / CQ Press

  • SAGE Journals
  • SAGE Knowledge
  • SAGE Research Methods
  • Help
Copyright © by SAGE Publications
Online ISSN: 1559-8977